Abstract:Engineering immune cells to target cancer is a rapidly advancing technology. The first commercial products, chimeric-antigen receptor (CAR) T cells, are now approved for hematologic malignancies. However, solid tumors pose a greater challenge for cellular therapy, in part because suitable cancer-specific antigens are more difficult to identify and surrounding healthy tissues are harder to avoid. In addition, impaired trafficking of immune cells to solid tumors, the harsh immune-inhibitory microenvironment, and variable antigen density and presentation help tumors evade immune cells targeting cancer-specific antigens. To overcome these obstacles, T cells are being engineered to express defined T-cell receptors (TCR). Given that TCRs target intracellular peptides expressed on tumor MHC molecules, this provides an expanded pool of potential targetable tumor-specific antigens relative to the cell-surface antigens that are targeted by CAR T cells. The affinity of TCR T cells can be tuned to allow for better tumor recognition, even with varying levels of antigen presentation on the tumor and surrounding healthy tissue. Further enhancements to TCR T cells include improved platforms that enable more robust cell expansion and persistence; coadministration of small molecules that enhance tumor recognition and immune activation; and coexpression of cytokine-producing moieties, activating coreceptors, or mediators that relieve checkpoint blockade. Early-phase clinical trials pose logistical challenges involving production, large-scale manufacturing, and more. The challenges and obstacles to successful TCR T-cell therapy, and ways to overcome these and improve anticancer activity and efficacy, are discussed herein.

Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

From Therapeutic Antibodies to Chimeric Antigen Receptors (cars): Making Better CARs Based on Antigen-Binding Domain

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

[Cell therapy's poster child: Chimeric antigen receptor T cell therapy]

CAR‐T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

New development in CAR-T cell therapy

Emerging Strategies in TCR-Engineered T Cells

Engineered T-cell Receptor T Cells for Cancer Immunotherapy

Anti-CD19 CAR T cells potently redirected to kill solid tumor cells

New Chimeric Antigen Receptor Design for Solid Tumors